Literature DB >> 9142213

Altered transcriptional regulation of the insulin-like growth factor 2 gene in human hepatocellular carcinoma.

K Uchida1, M Kondo, S Takeda, H Osada, T Takahashi, A Nakao, T Takahashi.   

Abstract

The insulin-like growth factor 2 (IGF2) gene is regulated in a complex manner, involving developmentally regulated use of four different promoters as well as transcriptional repression of the maternal allele due to genomic imprinting. It has been well documented that liver is an exceptional organ in which overall transcription from the four IGF2 promoters is markedly imbalanced towards preferential paternal expression only in fetal life, this being relaxed during the postnatal period, resulting in biallelic expression thereafter. We previously reported a marked allelic-expression imbalance in the overall transcription of IGF2 in hepatocellular carcinoma (HCC), leading to preferential expression nonrandomly from the paternal allele. The study presented here, using 18 HCC specimens taken directly from patients, showed that this molecular change often reflects promoters switching from the adult P1 promoter to the fetal P2, P3, and P4 promoters. Interestingly, however, we found that restoration of allele-specific expression of the P1 promoter nonrandomly from the paternal allele was also frequent in HCC suggesting retention of an imprint for paternal expression from the P1 promoter of IGF2 in adult normal liver and altered availability of its modifying factor or factors in HCC. Further studies of the molecular mechanisms involved in the fluctuation of promoter usage and genomic imprinting of IGF2 are warranted to gain an insight into the biology of the liver in terms of development and oncogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9142213

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  18 in total

1.  Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinoma.

Authors:  Philippe Couvert; Alain Carrié; Jacques Pariès; Jenny Vaysse; Audrey Miroglio; Antoine Kerjean; Pierre Nahon; Jamel Chelly; Jean-Claude Trinchet; Michel Beaugrand; Nathalie Ganne-Carrié
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

2.  Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma.

Authors:  Zhi-Zhen Dong; Deng-Fu Yao; Deng-Bing Yao; Xin-Hua Wu; Wei Wu; Li-Wei Qiu; Dao-Rong Jiang; Jian-Hua Zhu; Xian-Yong Meng
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

Review 3.  The IGF axis and hepatocarcinogenesis.

Authors:  J G Scharf; F Dombrowski; G Ramadori
Journal:  Mol Pathol       Date:  2001-06

4.  FSH Regulates IGF-2 Expression in Human Granulosa Cells in an AKT-Dependent Manner.

Authors:  Sarah C Baumgarten; Scott M Convissar; A Musa Zamah; Michelle A Fierro; Nicola J Winston; Bert Scoccia; Carlos Stocco
Journal:  J Clin Endocrinol Metab       Date:  2015-06-12       Impact factor: 5.958

5.  IGF-II promoter methylation and ovarian cancer prognosis.

Authors:  A C Beeghly; D Katsaros; A L Wiley; I A Rigault de la Longrais; A T Prescott; H Chen; M Puopolo; T J Rutherford; H Yu
Journal:  J Cancer Res Clin Oncol       Date:  2007-06-14       Impact factor: 4.553

Review 6.  Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

7.  Loss of imprinting and allelic switching at the DLK1-MEG3 locus in human hepatocellular carcinoma.

Authors:  Sumadi Lukman Anwar; Till Krech; Britta Hasemeier; Elisa Schipper; Nora Schweitzer; Arndt Vogel; Hans Kreipe; Ulrich Lehmann
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

8.  Anti-insulin-like growth factor-IIP3 DNAzymes inhibit cell proliferation and induce caspase-dependent apoptosis in human hepatocarcinoma cell lines.

Authors:  Min Zhang; Gregor P C Drummen; Su Luo
Journal:  Drug Des Devel Ther       Date:  2013-10-04       Impact factor: 4.162

9.  Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma.

Authors:  Federica Ragusa; Nadia Panera; Silvia Cardarelli; Marco Scarsella; Marzia Bianchi; Stefano Biagioni; Mauro Giorgi; Anna Alisi; Mara Massimi
Journal:  Cancers (Basel)       Date:  2021-05-01       Impact factor: 6.639

10.  Development of IGF signaling antibody arrays for the identification of hepatocellular carcinoma biomarkers.

Authors:  Qi Zhou; Ying-Qing Mao; Wei-Dong Jiang; Yun-Ru Chen; Ren-Yu Huang; Xiang-Bing Zhou; Ya-Feng Wang; Zhi Shi; Zhong-Sheng Wang; Ruo-Pan Huang
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.